The thesis in one sentence: ALCH is trading below its C$1.00 IPO price while the company is moving from years of validation into commercialization; the near-term issue is completing counterparties’ approvals and sign-offs, not a lack of operating activity.
The pullback since Alchemy Labs began trading is obvious. The more important question is what has happened inside the business during the same period.
Since the July IPO, Alchemy has expanded its ExoShield ULTRA Pro product coverage, signed a paid defence-development agreement and reported a significant improvement in second-quarter gross margin. That is not an absence of news. It is a company working through the period between technical validation and commercial conversion.
Our view is that the next phase depends on sign-offs. Programs involving large automotive fleets, original equipment manufacturers, defence suppliers and government organizations do not move at the speed of a small-cap stock chart. Internal approvals, technical milestones, contracting and counterparties’ timelines must be completed before Alchemy can announce definitive commercial outcomes.
That is why September and October matter. Those months are the next windows in which we expect some of this work to become visible. This is our expectation based on the due diligence assembled around the company—not formal timing guidance from Alchemy.
Disclosure: Members of the Stock Avengers community, including contributors to this due diligence, hold ALCH shares. No compensation was received for this article. This is not financial advice.
The IPO Price and the Operating Story Are Moving on Different Timelines
Alchemy completed its IPO on July 9, 2026, issuing 13,738,447 units at C$1.00 for gross proceeds of approximately C$13.74 million. Trading began on July 13.
The shares subsequently moved below the IPO price. That price action should not be ignored, but it should not be mistaken for evidence that the company stopped progressing.
Three notable disclosures followed the IPO:
August 4: ExoShield added Ford F-Series coverage, expanding the ULTRA Pro portfolio to more than 20 vehicle models.
August 13: Alchemy entered a paid non-recurring engineering agreement to advance Crypsis in Canadian defence textile applications.
August 19: The company reported Q2 revenue growth, its first Crypsis revenue contribution and a substantially improved gross margin.
The market price declined during a period in which the company continued to issue operating updates. The gap is therefore not “news versus no news.” It is the difference between development news and the larger commercial sign-offs investors ultimately want to see.
What Alchemy Is Building
Alchemy is not a single-product story. It has two distinct commercialization platforms.
ExoShield: Automotive Protection
ExoShield develops windshield-protection films and related automotive coatings. Modern windshields increasingly include cameras, sensors and advanced driver-assistance systems, making replacement and recalibration more expensive for consumers, dealerships and fleets.
The commercial attraction of ExoShield ULTRA Pro is not only its protective performance. It is also the installation model.
According to the investor materials reviewed in our due diligence, ULTRA Pro can be installed substantially faster than traditional bulk windshield-protection films. A shorter installation can allow a shop to complete more jobs and potentially earn more gross profit per hour.
That matters because installers are not merely a distribution channel. If a product improves their economics, they have a direct reason to recommend and sell it. This is the installer-driven flywheel that makes the comparison to XPEL relevant: the product can scale partly because the people installing it are economically motivated to promote it.
The Q2 update showed tangible movement:
The first six ExoShield ULTRA Pro aftermarket kit models were launched during the quarter.
On August 4, Ford F-Series models were added.
The portfolio had expanded to more than 20 vehicle models.
Management said it expects to continue introducing additional kits.
The company has spent years building installer relationships, product knowledge and manufacturing capability. The IPO capital gives it additional resources to turn that foundation into a broader commercial rollout.
The Automotive Pipeline Is Larger Than the Current Revenue Base
Our due diligence identified several automotive and fleet opportunities discussed in company materials and management communications:
Hertz: approximately C$60 million of annual opportunity
SIXT: approximately C$20 million, with a Phase 2 pilot discussed
Mercedes-Benz Buses: approximately C$7.2 million following a multi-stage qualification process
New York City Transit: approximately C$2 million, associated with pilot activity
U.S. Army Black Hawk follow-on work: approximately C$0.5 million
VinFast: OEM discussions following the Mercedes-Benz validation work
These figures should be understood correctly. They are opportunity estimates, not booked revenue, signed purchase orders or guarantees.
But that distinction is also the point of the current setup. The market is waiting for one or more identified opportunities to move through final approvals and become a definitive commercial commitment. The pipeline does not need every opportunity to convert for the company’s revenue profile to look materially different.
A major reference customer could also change the quality of every conversation that follows. Automotive OEMs and fleet operators are conservative. Once a product has completed a lengthy qualification with a recognized organization, later discussions begin with an externally validated reference rather than an unproven claim.
Crypsis: From Validation Toward Commercial Integration
Crypsis is Alchemy’s thermal-signature-management platform for defence and security applications.
The technology is designed to reduce detectability across visual and infrared spectrums. More importantly, Crypsis is not limited to one finished garment or one piece of equipment. The nanoparticle-based coatings can potentially be integrated into textiles and rigid substrates, including uniforms, shelters, vehicles, aircraft-related surfaces and other defence equipment.
This creates a different scaling model from manufacturing every end product internally.
Alchemy’s strategy is to work with established defence manufacturers, suppliers and prime contractors. Those partners contribute application engineering, manufacturing capacity and access to procurement channels. Alchemy contributes the material technology, technical knowledge and intellectual property.
That model was visible in the August 13 NRE agreement.
Under the agreement, Alchemy and a Canadian textile-based systems manufacturer that supplies the Department of National Defence will collaborate on the integration of Crypsis into textile-based defence applications. The development work has an estimated total cost of C$250,000, with Alchemy compensated primarily for engineering and technical services.
The program is expected to proceed through three development phases. Advancement between phases depends on technical milestones and mutual agreement. If the work is completed successfully, the parties may negotiate a separate commercial agreement for production.
This is an important distinction:
The technology has already undergone development and field validation with DND.
Alchemy is being paid to complete application-specific engineering with an established supplier.
The next step is a separate commercial production agreement.
The current stage is therefore not simply “more research.” It is the bridge between validated technology and a potentially repeatable product relationship.
Why the Sign-Offs Matter
A small public company can disclose its own progress. It cannot unilaterally announce a counterparty’s approval before documentation, technical milestones and commercial terms are complete.
That is the period ALCH appears to be in now.
The work can be active without being immediately reportable. Engineering can advance. Partners can test applications. Commercial teams can negotiate. Internal committees can review budgets and procurement. None of that becomes a definitive announcement until the required parties sign off.
This is why we do not interpret the post-IPO price decline as proof of an empty pipeline.
Our expectation is that September and October should begin clarifying which programs are ready to cross from activity into disclosure. The items we are watching include:
Completion of milestones and sign-offs connected to the Canadian defence textile NRE
Additional defence NRE agreements or prime-contractor programs
Commercial progression involving Mercedes-Benz Buses
Expansion of the SIXT pilot or movement in other fleet programs
Further ExoShield ULTRA Pro model launches and installer adoption
Evidence that the IPO-funded manufacturing and commercial expansion is increasing capacity
A delay in disclosure and a lack of underlying work are not the same thing.
Q2 Was a Pre-IPO Snapshot
Alchemy reported Q2 revenue of C$581,027, an increase of 16.9% from C$496,871 in the comparable quarter.
The composition is also worth noting:
ExoShield generated C$509,195.
Crypsis generated its first reported contribution of C$71,382.
Gross profit was C$224,803.
Gross margin improved to 38.7%, compared with a slightly negative gross margin in Q2 2025.
The operating loss increased as the company invested in engineering, sales, business development and infrastructure. However, the July IPO occurred after the June 30 quarter-end.
That timing matters. The Q2 balance sheet and income statement do not show a company that had a full quarter to deploy C$13.74 million of new gross proceeds. They show the business immediately before the capital intended to accelerate commercialization arrived.
Looking only at trailing revenue risks valuing Alchemy as though the IPO funded a continuation of the previous stage. The more relevant question is what the company builds with that capital after the quarter closed.
The Capitalization Misunderstanding
The IPO closing release reported 54,549,120 common shares issued and outstanding. It also reported that 14,722,612 common shares were held in escrow.
That post-closing figure is important because some discussion has treated pre-IPO convertible securities as though they remain an entirely separate future block to be added again. Our reading of the prospectus and post-IPO capitalization is that the closing share count already reflects the relevant conversion mechanics completed in connection with the listing.
The IPO units themselves included one common share and one-half warrant, with each whole warrant exercisable at C$1.50 until July 9, 2028, subject to the company’s acceleration right.
Investors should distinguish among:
Shares already included in the reported post-IPO count
Escrowed principal shares that release over time
IPO warrants exercisable at C$1.50
Future equity that would only arise if outstanding options or warrants are exercised
Treating the same conversion shares as both current shares and an additional future conversion can materially distort the capitalization analysis.
Two Independent Paths to Commercialization
The part of the ALCH thesis we believe is most underappreciated is the presence of two independent scaling engines.
ExoShield can grow through product availability, vehicle-model coverage, installer economics, dealerships, fleets, insurers and OEM programs.
Crypsis can grow through paid engineering, material sales, licensing and integration into products manufactured by established defence suppliers.
One platform does not need to wait for the other.
If an automotive sign-off takes longer, a defence program may advance first. If defence procurement moves slowly, ULTRA Pro kit adoption and fleet programs can continue progressing. Multiple commercialization paths reduce the dependence on one all-or-nothing announcement.
Management’s investor presentation outlined a 2027 revenue target of approximately C$19.54 million, divided almost evenly between ExoShield and Crypsis. The same due diligence also identified larger opportunities and non-dilutive funding applications that were not relied upon in that base case.
The significance is not that every pipeline number must become revenue. It is that the base case can be supported by more than one route, while a major commercial conversion could change expectations well before all associated revenue appears in the financial statements.
What September and October Can Tell Us
The next two months do not need to deliver every potential contract.
They need to show that the transition is continuing.
A paid NRE moving into its next phase, an additional defence agreement, a fleet expansion, an OEM sign-off or evidence of accelerating ULTRA Pro distribution would each provide information about the same central question:
Can Alchemy convert six years of technical work into recurring commercial revenue?
The IPO financed the attempt. The August updates showed that work is continuing. September and October should help investors judge the pace at which counterparties are completing the approvals required to make that work visible.
Final Takeaway
ALCH is below its C$1.00 IPO price. That fact is not being dismissed.
But the reason matters.
The company has not gone silent. Since listing, it has expanded the automotive portfolio, entered a paid defence-development program and reported improving revenue and gross margin. The larger opportunities are taking longer because commercial and defence programs require technical milestones, counterparties’ approvals and final sign-offs.
Our thesis is not that the stock must recover simply because it is below the IPO price.
Our thesis is that the market is currently pricing the wait while Alchemy is building the evidence required for commercialization.
The next meaningful information should come from execution: signed agreements, completed phases, expanded pilots, production commitments and continued product rollout.
September and October are the windows we are watching.
Sources
This article reflects our interpretation of public filings, company disclosures, investor materials and independent due diligence. Forward-looking opportunities are not guaranteed contracts or revenue. This is not financial advice.
Continue the Conversation
Join the free Stock Avengers Discord for ongoing ALCH discussion, follow-ups and analysis of other stocks: